Introgen Therapeutics Inc

Industry:	Pharmaceuticals, Biotechnology
Ranking:	Russell 3000
Revenues:	$1 Million
Employees:	74

Description

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. The Company is developing product candidates to treat a range of cancers using tumor suppressors, cytokines and other targeted molecular therapies. These agents are designed to increase production of normal cancer-fighting proteins that act to overpower cancerous cells, stimulate immune activity and enhance conventional cancer therapies. The Company's products work by acting as templates for the transient in vivo production of proteins that have pharmacological properties. The resultant proteins engage disease-related molecular targets or receptors to produce specific therapeutic effects. Introgen Therapeutics' product candidate is ADVEXIN therapy.
(Source: 10-K)

Products & Services

targeted molecular therapies, biopharmaceutical products

View More Statistics

Site Statistics

Monthly Unique Visitors:	1,330
Site Rank:	885,205
Trust Rating:	Neutral
Stats by

News Archive

Gene-Therapy Death Likely Due To Age, Weak Immunity. BIOWORLD Today; 11/3/2009 ...statistically significant improvement in lung function. (See BioWorld Today, March 18, 2005.) Dunn covers Introgen Therapeutics Inc., of Austin, Texas, which at this year's meeting of the American Society of Clinical Oncology reported... ...more

U.S. Patent Disclosures. BIOWORLD Today; 11/3/2009 ...Compartmentalization of Expression) method. That technology is designed to enable in situ biomarker analysis for pathology. Introgen Therapeutics Inc., of Austin, Texas, was awarded U.S. Patent No. 7,235,391, titled "Formulations of Adenovirus... ...more

Genzyme Purchasing Rights In Ceregene Parkinson's Deal. BIOWORLD Today; 11/3/2009 ...little difficult," said Stephen Dunn, analyst with Dawson James, dryly understating the case. Dunn covers Introgen Therapeutics Inc., of Austin, Texas, which at this year's meeting of the American Society of Clinical Oncology reported... ...more